Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Evocutis
Evocutis
Activities:
Regulatory
Research & Development
Skin Care
X
LinkedIn
Trending Articles
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Broughton receives flexible scope ISO 17025 accreditation
New certification allows accreditation without prior approval
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Skin Care
Venn Life Sciences acquires trading assets of Evocutis
Including intellectual property rights to Labskin and anti-acne compound SYN1113
Regulatory
Evocutis and Bradford University Collaborate on pigmented LabSkin
Aim to discover improved ways of investigating common pigment-related skin conditions
Regulatory
Evocutis secures first contracts for LabSkin living skin equivalent
Offers an alternative to ethically sensitive and expensive animal and human volunteer testing
Research & Development
Evocutis joins European platform to promote alternatives to animal testing
After making presentation about its LabSkin technology
Ingredients
Syntopix develops microemulsions for healthcare and cosmetic products
Identifies two green surfactants for oral care
Manufacturing
Syntopix plans to buy Leeds Skin
Key attraction of acquisition is Leeds Skin’s LabSkin technology
Ingredients
Syntopix to develop new microemulsions
Wins support from Intelligent Formulation
Subscribe now